11
Aug
2010
Posted in I - Series D, Q - 3Q10, R - SOUTH WEST, X - Inflammation, X - Renal, XX - TX
Reata Pharmaceuticals (Irving, TX) a clinical-stage small molecule company focused on inflammation modulation in chronic kidney disease, closed a $78M Series D financing. Participants include CPMG and Novo Ventures.